Research Study

Combined Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects With Moderately to Severely Active Ulcerative Colitis
Principal Investigator 
Baljinder Salh

Overview

Body Locations and Systems 
Ulcerative Colitis
ClinicalTrials.gov# 
NCT02914522
Status 
Recruiting
Study Start/End 
Sep 7, 2017 to Dec 31, 2019
Locations 
Diamond Health Care Centre
Name/Title 
Jo-Ann Ford, Clinical Research Coordinator
Phone 
604-875-5705
Email Address 
jo-ann.ford@vch.ca
Purpose of Study 

The primary objectives of this study are to evaluate the safety and efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced.

Eligibility 

Visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.